Company facts
Early-stage
- Founded
- 2022
- Employees
- 5
- Headquarters
- United States
About
We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.